LOS ANGELES — Xdemvy yielded symptom improvements in patients with Demodex blepharitis, according to Kendall E. Donaldson, MD, MS.
At the American Society of Cataract and Refractive Surgery meeting, Donaldson presented data from Orion, a real-world, multicenter study that looked at the burden of Demodex blepharitis in 300 patients. Patients treated with Xdemvy (lotilaner ophthalmic solution 0.25%, Tarsus Pharmaceuticals) “improved significantly in their symptoms” at 6 months while visual analog scale scores decreased. Symptoms increased in patients who were not treated with